PR-HEALTH-1st-HUMAN-VACCINATIONS SAPA PR--THE FIRST HUMAN VACCINATIONS OF MYMETICS' PREVENTATIVE...

Jan 19, 2010 at 09:28 AM
ISSUED BY: GLOBE NEWSWIRE


THE FIRST HUMAN VACCINATIONS OF MYMETICS' PREVENTATIVE HIV
VACCINE CANDIDATE ARE WELL TOLERATED

EPALINGES, Switzerland, Jan. 19, 2010 (GLOBE NEWSWIRE) --
Mymetics Corporation, a pioneer in the development of mucosal
focused vaccines for human infectious diseases, announced today
that following the vaccination of human volunteers as part of a
clinical Phase I trial, the company's first preventative HIV
vaccine has been well tolerated.

This Phase I trial follows the breakthrough results Mymetics has
achieved in macaque monkeys last year. During these pre-clinical
studies Mymetics' HIV vaccine provided full protection of
vaccinated non-human primates against multiple heterologous live
virus challenges, while the placebo group became fully infected.
These levels of protection have not been seen before in this type
of HIV studies.

HIV, the virus that causes AIDS, infected about 2.7 million new
people in 2008, while an estimated 2 million people died in that
same period. HIV related illness remains one of the leading causes
of death globally and is projected to continue as a significant
global cause of premature mortality in the coming decades.

Until now there has been no vaccine against HIV. "Mymetics
vaccine approach is unique in the sense it aims to build protection
at the mucosal layer, which is the largest port of entry for many
pathogens," stated Jacques François Martin, CEO of Mymetics
Corp.

"The start of this first Phase I is a very important step for
Mymetics in its development of a successful preventative HIV
vaccine," stated Sylvain Fleury, Chief Scientific Officer of
Mymetics Corp. The placebo controlled, double blinded, single site
trial will study the safety and tolerance of the Mymetics HIV
preventative vaccine in healthy volunteers. During the last four
weeks, the first people have been successfully vaccinated and the
vaccine was very well tolerated. In total 24 people will be
vaccinated and monitored over a 12 month period.

About Mymetics

Swiss based, US biotechnology company (OTCBB:MYMX) focused on
the development of the next generation preventative vaccines for
infectious diseases, with 5 vaccines in the pipeline: HIV-1/AIDS,
Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex
Virus. Mymetics core technology and know-how is based on the use of
virosomes in combination with rationally designed antigens to
induce protection acting on early transmission and infection
events, including the mucosal immune response as a first barrier
against the infection. Mymetics believes this approach allows it to
develop preventative vaccines for a broad range of diseases.

Mymetics has started a Phase I for its HIV-1 vaccine. The Phase
1b clinical trial for the Malaria vaccine with children in Tanzania
has been completed, while the RSV and the HSV vaccine candidates
are in pre-clinical phase. The Influenza virus is out-licensed to
Solvay Pharmaceuticals (now Abbott). For further information,
please visit: www.mymetics.com

The Mymetics Corporation logo is available at
www.globenewswire.com/newsroom/prs/?pkgid=5478

Forward looking statements

The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements, which are
identified by the words "believe," "expect,"
"anticipate," "intend," "plan" and
similar expressions.

The statements contained herein which are not based on
historical facts are forward-looking statements that involve known
and unknown risks and uncertainties that could significantly affect
our actual results, performance or achievements in the future and,
accordingly, such actual results, performance or achievements may
materially differ from those expressed or implied in any
forward-looking statements made by or on our behalf. These risks
and uncertainties include, but are not limited to, risks associated
with our ability to successfully develop and protect our
intellectual property, our ability to raise additional capital to
fund future operations and compliance with applicable laws and
changes in such laws and the administration of such laws. See
Mymetics' most recent Form 10-K for a discussion of such risks,
uncertainties and other factors. Readers are cautioned not to place
undue reliance on these forward-looking statements which speak only
as of the date the statements were made.

CONTACT: Mymetics Corporation
Ronald Kempers, COO
+41 21 653 4535
www.mymetics.com